• Clinico-pathogenetic substantiation and experience of the use of interferon alpha 2b in children with acute respiratory viral infections

Clinico-pathogenetic substantiation and experience of the use of interferon alpha 2b in children with acute respiratory viral infections

SOVREMENNAYA PEDIATRIYA.2016.1(73):87-92; doi10.15574/SP.2016.73.87

Clinico-pathogenetic substantiation and experience of the use of interferon alpha 2b in children with acute respiratory viral infections

Marushko Yu. V., Sabadash E. E., Zelena N. A. 
A.A. Bogomolets National Medical University, Kiev, Ukraine

Objective. To evaluate the efficacy and safety of interferon preparations in children under three years with acute respiratory viral infections. Patients and methods. A total of 97 observed children with a diagnosis ARVI has been consulted by doctor at 152 days after the onset of the disease. In the main group in the complex treatment additionally was prescribed nasal interferon alpha 2b «Nazoferon» in the age dosages. Children of the control group had received conventional treatment only.

Results. Due to the application of Nazoferon was observed a decrease in the duration as of the main symptoms of the disease (catarrhal phenomena and temperature reaction), so the effects of intoxication. On the fifth day of treatment the difference between clinical parameters was more pronounced. It is found that Nazoferon well tolerated, does not cause discomfort on the part of the respiratory system.

Conclusions. The good clinical efficacy and lack of adverse reactions allow recommending Nazoferon for use in pediatric patients. Application of Nazoferon is important to start from the early 152 days of the disease. Allow it to use as a prophylactic measure.

Key words: acute respiratory viral infections, infants, treatment, Nazoferon.

REFERENCES 
1. Couch RB, Atmar RL, Cate TR et al. 2009. Contrasting Effects of Type I Interferon as a Mucosal Adjuvant for Influenza Vaccine in Mice and Humans. Vaccine. 27(39): 344—348. http://dx.doi.org/10.1016/j.vaccine.2009.06.084; PMid:19607949 PMCid:PMC277820 
2. Brassard DL, Grace MJ, Bordens RW. 2002. Interferon-α as an immunotherapeutic protein. Journal of Leukocyte Biology. 71; 4: 565—581. PMid:11927642
3. Kugel D, Kochs G, Obojes K et al. 2009. Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets. J Virol. 83(8): 843—851. http://dx.doi.org/10.1128/JVI.02453-08; PMid:19193792 PMCid:PMC2663257 
4. Larussa P. 2011. Pandemic novel 2009 H1N1 influenza: what have we learned? Seminars in Respiratory and Critical Care Medicine. 32; 4: 393—399. http://dx.doi.org/10.1055/s-0031-1283279; PMid:21858744 
5. Steel J, Staeheli P, Mubareka S et al. 2010. Lowen Transmission of Pandemic H1N1 Influenza Virus and Impact of Prior Exposure to Seasonal Strains or Interferon Treatment. J Virol. 84(1): 21—26. http://dx.doi.org/10.1128/JVI.01732-09; PMid:19828604 PMCid:PMC2798408 
6. Mangan NE, Fung KY. 2012. Type I interferons in regulation of mucosal immunity. Immunol cell biol. 90(5). http://dx.doi.org/10.1038/icb.2012.13 
7. Monto AS. 2004. Occurrence of respiratory virus: time, place and person. Pediatric Infectious Disease Journal. 23; Suppl 1: 58—64. http://dx.doi.org/10.1097/01.inf.0000108193.91607.34; PMid:14730271 
8. Pariani E, Martinelli M, Canuti M. Influenza and Other Respiratory Viruses Involved in Severe Acute Respiratory Disease in Northern Italy during the Pandemic and Postpandemic Period (2009—2011). BioMed Research International. 2014(2014), Article ID 241298, 5 pages. http://dx.doi.org/10.1155/2014/241298
9. Xi Y, Day SL, Jackson RJ, Ranasinghe C. 2012. Role of novel type I interferon epsilon in viral infection and mucosal immunity. Mucos Immunol. 23. Epub. 
10. Samuel Charles E. 2001. Antiviral Actions of Interferons. Clinical Microbiology Reviews. 14;4: 778—809. http://dx.doi.org/10.1128/CMR.14.4.778-809.2001; PMid:11585785 PMCid:PMC89003 
11. Yohichi Kumaki, Jane Ennis, Ramtin Rahbar et al. 2011. Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model. Antiviral researches. 89(1): 75—82. http://dx.doi.org/10.1016/j.antiviral.2010.11.007; PMid:21093489 PMCid:PMC3018546 
12. Swerdlow DL, Finelli L, Bridges CB. 2011. 2009. H1N1 influenza pandemic: field and epidemiologic investigations in the united states at the start of the first pandemic of the 21st century. Clinical Infectious Diseases. 52; Suppl 1: 1—3. http://dx.doi.org/10.1093/cid/ciq005; PMid:21342879 
13. Van Hoeven N, Belser JA, Szretter KJ et al. 2009. Tumpey Pathogenesis of 1918 Pandemic and H5N1 Influenza Virus Infections in a Guinea Pig Model: Antiviral Potential of Exogenous Alpha Interferon To Reduce Virus Shedding. J Virol. 83(7): 851—861. http://dx.doi.org/10.1128/JVI.02174-08; PMid:19144714 PMCid:PMC2655560

Содержание журнала Full text of article